VJHemOnc is committed to improving our service to you

EHA 2020 | Azacitidine and decitabine in treatment naive AML patients

VJHemOnc is committed to improving our service to you

Amer Zeidan

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the comparative results of azacitidine and decitabine from a large prospective Phase III study in treatment-naive acute myeloid leukemia (AML) not eligible for intensive chemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter